Ser3

Site Information
_____MAsGVTVNDE SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 2048097

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 14 , 15 , 16 , 17 , 18 , 19 , 20 )
Disease tissue studied:	breast cancer ( 7 , 10 ) , breast ductal carcinoma ( 7 ) , HER2 positive breast cancer ( 2 ) , luminal A breast cancer ( 2 ) , luminal B breast cancer ( 2 ) , breast cancer, surrounding tissue ( 2 ) , breast cancer, triple negative ( 2 , 7 ) , cervical cancer ( 18 ) , cervical adenocarcinoma ( 18 ) , lung cancer ( 10 ) , non-small cell lung cancer ( 10 ) , ovarian cancer ( 7 ) , melanoma skin cancer ( 5 )
Relevant cell line - cell type - tissue:	'muscle, skeletal' ( 14 ) , 293 (epithelial) [AT1 (human), transfection, AT1R stable transfected HEK293] ( 16 ) , 293 (epithelial) ( 20 ) , 786-O (renal) [VHL (human), transfection] ( 4 ) , 786-O (renal) ( 4 ) , A498 (renal) ( 17 ) , A549 (pulmonary) ( 8 ) , breast ( 2 , 7 ) , BT-20 (breast cell) ( 10 ) , BT-549 (breast cell) ( 10 ) , Calu 6 (pulmonary) ( 10 ) , endothelial-aorta ( 11 ) , Flp-In T-Rex-293 (epithelial) [PRKD1 (human), genetic knockin] ( 12 ) , Flp-In T-Rex-293 (epithelial) ( 12 ) , H2009 (pulmonary) ( 10 ) , H2077 (pulmonary) ( 10 ) , H2887 (pulmonary) ( 10 ) , H322M (pulmonary) ( 10 ) , HCC1359 (pulmonary) ( 10 ) , HCC1937 (breast cell) ( 10 ) , HCC2279 (pulmonary) ( 10 ) , HCC366 (pulmonary) ( 10 ) , HCC4006 (pulmonary) ( 10 ) , HCC78 (pulmonary) ( 10 ) , HCC827 (pulmonary) ( 10 ) , HeLa (cervical) ( 1 , 6 , 9 , 19 ) , HeLa S3 (cervical) ( 18 ) , HOP62 (pulmonary) ( 10 ) , HUES-9 ('stem, embryonic') ( 15 ) , K562 (erythroid) ( 9 , 19 ) , LCLC-103H (pulmonary) ( 10 ) , LOU-NH91 (squamous) ( 10 ) , MCF-7 (breast cell) ( 10 ) , MDA-MB-231 (breast cell) ( 10 ) , MDA-MB-468 (breast cell) ( 10 ) , NCI-H1395 (pulmonary) ( 10 ) , NCI-H1648 (pulmonary) ( 10 ) , NCI-H2030 (pulmonary) ( 10 ) , NCI-H2172 (pulmonary) ( 10 ) , NCI-H322 (pulmonary) ( 10 ) , NCI-H460 (pulmonary) ( 10 ) , ovary ( 7 ) , WM239A (melanocyte) ( 5 )

Upstream Regulation
Treatments:	EGF ( 1 ) , ischemia ( 7 ) , vemurafenib ( 5 )

References
1	Huang H, et al. (2016) Simultaneous Enrichment of Cysteine-containing Peptides and Phosphopeptides Using a Cysteine-specific Phosphonate Adaptable Tag (CysPAT) in Combination with titanium dioxide (TiO2) Chromatography. Mol Cell Proteomics 15, 3282-3296 27281782 Curated Info
2	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
3	Boeing S, et al. (2016) Multiomic Analysis of the UV-Induced DNA Damage Response. Cell Rep 15, 1597-1610 27184836 Curated Info
4	Malec V, Coulson JM, Urbé S, Clague MJ (2015) Combined Analyses of the VHL and Hypoxia Signaling Axes in an Isogenic Pairing of Renal Clear Cell Carcinoma Cells. J Proteome Res 14, 5263-72 26506913 Curated Info
5	Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615 25850435 Curated Info
6	Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94 25159151 Curated Info
7	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
8	Kim JY, et al. (2013) Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells. Proc Natl Acad Sci U S A 110, 12414-9 23836654 Curated Info
9	Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71 23186163 Curated Info
10	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
11	Verano-Braga T, et al. (2012) Time-resolved quantitative phosphoproteomics: new insights into Angiotensin-(1-7) signaling networks in human endothelial cells. J Proteome Res 11, 3370-81 22497526 Curated Info
12	Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70 22496350 Curated Info
13	Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25 22424773 Curated Info
14	Lundby A, et al. (2012) Quantitative maps of protein phosphorylation sites across 14 different rat organs and tissues. Nat Commun 3, 876 22673903 Curated Info
15	Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3 21406692 Curated Info
16	Christensen GL, et al. (2010) Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics 9, 1540-53 20363803 Curated Info
17	Schreiber TB, et al. (2010) An integrated phosphoproteomics work flow reveals extensive network regulation in early lysophosphatidic acid signaling. Mol Cell Proteomics 9, 1047-62 20071362 Curated Info
18	Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3 20068231 Curated Info
19	Pan C, Olsen JV, Daub H, Mann M (2009) Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics 8, 2796-808 19651622 Curated Info
20	Gauci S, et al. (2009) Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach. Anal Chem 81, 4493-501 19413330 Curated Info